|
|
|
| Clinical efficacy of modified Chinese medicine iontophoresis in the treatment of nonalcoholic fatty liver disease |
| YIN Xiaofei SUN Min LI Huiling LU Gendi |
| Traditional Medical Rehabilitation Treatment Center, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China |
|
|
|
Abstract Objective To investigate the effect of modified Chinese medicine iontophoresis on patients with nonalcoholic fatty liver disease. Methods Seventy-two patients with nonalcoholic fatty liver disease were selected from July 2017 to May 2018 in Department of Liver Disease, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine. According to the random number table method, they were randomly divided into control group and observation group, with 36 cases in each group. Control group was treated with conventional Chinese medicine iontophoresis on the basis of conventional treatment, while observation group was treated with improved Chinese medicine iontophoresis. Body mass index (BMI), traditional Chinese medicine syndrome integral, plasma total cholesterol, high-density lipoprotein, low-density lipoprotein, triglyceride levels and CAP value were compared between two groups. Results BMI and traditional Chinese medicine syndrome scores of two groups after treatment were significantly lower than before treatment (P < 0.05), but there was no significant difference between two groups after treatment (P > 0.05). The levels of total cholesterol, low-density lipoprotein and triglyceride in two groups were significantly lower than those before treatment (P < 0.05), and high-density lipoprotein was significantly higher than before treatment (P < 0.05). Triglyceride in observation group was lower than that in control group after treatment, the difference was statistically significant (P < 0.05). There was no significant difference in the levels of total cholesterol, high-density lipoprotein and low-density lipoprotein between two groups after treatment (P > 0.05). The CAP value of liver in two groups after treatment was significantly lower than that before treatment, observation group was significantly lower than control group, and the differences were statistically significant (P < 0.05). Conclusion Modified Chinese medicine iontophoresis can improve the curative effect of nonalcoholic fatty liver disease, and has the value of promotion.
|
|
|
|
|
|
[1] 吴东，高海燕，张淑玲，等.中药离子导入治疗脂肪肝的临床观察及护理[J].中外医疗，2014，33（7）：147-148.
[2] 张霞霞，徐有青.《2018年国际肝移植协会意见：非酒精性脂肪性肝炎的管理和治疗》摘译[J].临床肝胆病杂志，2019，35（1）：65-67.
[3] 钟燕，苏淑婷，宓余强.非酒精性脂肪性肝病治疗研究进展[J].实用肝脏病杂志，2019，22（1）：150-153.
[4] 范建高.中国非酒精性脂肪性肝病诊疗指南（2010年修订版）[J].中国医学前沿杂志：电子版，2012，4（7）：4-10.
[5] 李敏谦，林育，项磊，等.基于临床文献的非酒精性脂肪性肝病证候分布规律研究[J].世界中医药，2019，14（1）：25-30.
[6] 张华，刘平.中医证候量化研究的思路与方法探析[J].中国中医基础医学杂志，2009，15（8）：574-576.
[7] 徐晓鸾，孟繁坤，孙丽娟.超声弹性检测评价脂肪肝的应用研究[J].医学影像学杂志，2016，26（10）：1843-1846. [8] 中华医学会肝病学分会脂肪肝和酒精性肝病学组.非酒精性脂肪性肝病诊疗指南[J].现代医药卫生，2011，27（5）：641-643.
[9] Perumpail BJ，Khan MA，Yoo ER，et al. Clinical epidemiology and disease burden of nonalcoholic fatty liver disease [J]. World J Gastroenterol，2017，23（47）：8263-8276.
[10] 许炎煌，范建高.非酒精性脂肪性肝炎的药物治疗现状与对策[J].国际消化病杂志，2019，39（1）：7-11.
[11] Friedman SL，Neuschwander-Tetri BA，Mary R，et al. Mechanisms of NAFLD development and therapeutic strategies [J]. Nat Med，2018，24：908-922.
[12] Xiao J，Guo R，Fung ML，et al. Therapeutic approaches to non-alcoholic fatty liver disease：past achievements and future challenges [J]. Hepatobiliary Pancreat Dis Int，2013，12（2）：125-135.
[13] 金仙，白尊艳.中医情志护理对非酒精性脂肪性肝病的影响[J].护理与康复，2019，18（6）：84-86.
[14] 张良.绿茶瘦身汤离子导入法治疗非酒精性脂肪肝50例临床观察[J].世界最新医学信息文摘，2017，17（64）：84.
[15] 韩桂茹.活化清脂离子导入法治疗非酒精性脂肪肝50例临床观察[J].世界最新医学信息文摘，2016，16（38）：84.
[16] 陈瑜，高敏，赵庚.中药离子导入配合短波治疗非酒精性脂肪肝的临床观察[J].中国医学创新，2011，8（30）：42-43.
[17] 施爱辉，刘春颖，吴俊满.中药离子导入配合静脉点滴药物及综合疗法治疗重度脂肪肝的观察[J].中国现代药物应用，2013，7（2）：67-68.
[18] Friedrich-Rust M，Wunder K，Kriener S，et al. Liver fibrosis in viral hepatitis noninvasive assessment with acoustic radiationforce impulse imaging versus transient elastography [J]. Radiology，2009，252（2）：595-604．
[19] 陈蕾，陈路增.《2017年欧洲超声医学和生物学联合会肝脏弹性超声临床应用指南和建议》摘译[J].临床肝胆病杂志，2017，33（10）：1910-1915.
[20] Sasso M，Beaugrand M，de Ledinghen V. Controlled attenuation parameter（CAP）：a novel VCTETM guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis：preliminary study and validation in a cohort of patients with chronic liver disease from various causes [J]. Ultrasound Med Biol，2010，36（11）：1825-1835.
[21] 薄文，张锋利，李平，等.中药离子导入的治疗进展[J].中国中医药现代远程教育，2016，11（22）：150-153. |
|
|
|
